We were all wondering where you went. What was with the "hit and run"? :) I wouldn't say it is a serious position, but definitely not chump change. That's a nice list of investors though, for sure.
Yeah well I get lucky sometimes. Great news about Perceptive and Sphera. Not a huge amount of money put in, but any time a billion dollar fund participates in an offering for your company it brings a level of credibility.
OT, after a ton of research I opened a small position in ONCS last week. Thanks for the heads up.
Speaking of bowel movements. Why are you so "normal" on the ONCS board and such a turd on this one? It's kind of pathetic to be honest.
What's even more pathetic is you thinking that your posts trying to bring down the pps have any affect at all. It's not our fault you missed buying at $.25.
Quit trying so hard, it's embarrassing.
Yes, there is a chance. Check my thread below about the potential for fast-tracking, breakthrough designation etc...
If there were ever a candidate for breakthrough BCLI would be the one in my opinion. Given the fast mortality rate post ALS diagnosis, time and early treatment is of utmost importance. ALS has already shown that NurOwn is safe in patients and that it works in helping to halt the progression of the disease. A disease for which there is no current treatment.
They are already fast-tracked in Israel and it is a good sign that the FDA allowed them to start from Phase II in the USA. If the positive trend continues through Phase II, then I honestly do feel their is potential for BCLI to be designated for breakthrough status. Why have it if you don't award it to companies like BCLI?
All in my opinion.
Lebovits said they would need $7M to complete Phase II in the USA. So yes they have enough for Phase II. As for Phase III they will definitely need a new injection of cash. However, if Phase II goes as well as anticipated, I think BCLI will have a lot of options for raising funds in a non-dilutive way.
One thing that Brainstorm has going for them is that they are using one platform, NurOwn, to treat several different indications. Based on the data collected so far in the ALS trial, we know NurOwn is safe and well tolerated in humans. Once BCLI files IND's for other indications, what are the chances the FDA will make them go through a Phase I, a trial to test safety and tolerability, for the same product that has already proven to be safe? Considering that the key to success for treatment of these neurological diseases is early detection/treatment, I personally don't see the FDA forcing BCLI to prove safety again. Especially since lives are at risk. BCLI is already fast-tracked in Israel and they were able to start from Phase II in the USA, so I don't think this idea is too far out there.
On another, but related note. I have invested in and traded several biotech stocks in the past. BCLI is the one that I feel is the best candidate to be granted breakthrough therapy in the future. Since patients are given just 2-6 years to live post diagnosis of ALS, and if the treatment continues to prove that the progression of disease is actually halted in most patients (which there is no reason to think it won't), then I think is a realistic possibility. Why else have breakthrough therapy designation if you don't award it to companies like Brainstorm.
It was encouraging to see the Israeli Ministry of Health give in to the wishes (demands?) of the IDF and allow the soldier to have a second round of treatment on compassionate grounds. I believe this is a sign of things to come as more stem cell therapies prove not only to be safe, but effective in early stages of trials for life threatening diseases.
As always, would love to hear feedback. Thanks!
Thanks for the advice. The only problem is, if I would have listened to it I would have missed out from buying this stock in the low teens. My philosophy (buy when I believe it is undervalued) has already proved successful for me with this company regardless of what happens from here on out. Any appreciation at this point is icing on the cake.
You obviously don't have much knowledge on how to capitalize on early-stage biotechs that are not yet bringing in revenue, and likely miss the boat with them. That is OK though, I completely understand why one would rather play it safe. Those who lack experience are probably better off aiming for those 10% annual returns via safer blue chip stocks. Again, nothing wrong with that. Just different.
Word of advice. Don't try so hard to sound like a big shot know-it-all, especially when your knowledge is limited. There is nothing more pathetic than a keyboard commando trying to bully people around on an internet message board. You may have sold at a loss, sold to soon, or are looking to buy back cheaper. I get it. But don't take it out in others. You don't have to allow yourself to turn into a typical boring internet bully. There IS help for you and others like you. We hear your cries. Just reach out to someone close to you, someone who you can trust.
You said you are done with this thread so I guess we won't be hearing back from you.
Good luck and all the best!
It seems as though our investing philosophies are different. I look to buy stocks that are undervalued before the rest of the market realizes their potential. It seems you are more interested in waiting until they are are already well established and "safer". Nothing wrong with that, just different than what I am interested in. My approach is for sure more risky, but allows for a much higher return on investment if I get it right.
Of course I am talking about what may or may not happen in the future. Is there stock where you are guaranteed to know exactly what will happen in the future? Fundamentals are relative to the particular stage of the company. In this instance, the fundamentals of BCLI's are strong. Compared to most other early-stage biotech companies they have a solid balance sheet, good capital structure (share count could be lower, but it is not terrible), and a product that is proving to work for a diseases that have no treatment. A huge revenue stream is not necessary for a stock to be able to jump in valuation. At $67M I think it is currently very undervalued at this stage. A jump to $100M in valuation would be a nice gain for me even without having the revenue stream you are speaking of.
"There is absolutely no basis for that statement, the fundamentals are terrible and will be for a long time. What strength are you talking about anyway?"
Simple. No debt, plenty of cash for the foreseeable future, no shareholder liability, extremely positive trial results so far for a product aimed to treat a disease for which there is no current treatment, just commenced a Phase II trial in the USA with the absolute best hospitals and medical professionals in the ALS field, new CEO who is very well respected in the field, looking to up-list to a national stock exchange in the near future, have other indications in the works, still virtually unknown in the USA market, fully funded trial about to commence in Brazil, trial data to be published in a peer-reviewed journal in or around August, insiders accumulating shares, toxic funding and warrants with anti-dilution provisions now a thing of the past, very undervalued compared to other similar early-stage biotechs, and I could go on and on. What about the fundamentals don't you like besides the silly blanket statement that they are just terrible, just because? lol!
Sure commercialization is a long way away, but that doesn't mean it can't appreciate in value before then. I can give you a long list of companies that have a high market valuation and are still far from commercialization. I am interested in investing in undervalued companies with great potential before the rest of the market recognizes it. It has already been a great investment for me to this point. It sounds like you only want to invest after the major growth has occurred.
Best of luck!
Despite it being a different market this year (which I agree with), your point about CUR being at $.40 then to $1 then to its current pps of over $4, and being able to up-list without doing a reverse split only solidifies my point, that it can and has happened. It's tough to gauge the market so you never know would could or couldn't happen.
Again, unlikely. Just throwing it out there. I still fully expect a r/s and up-list.
Thanks for the response. For the record, I am totally in favor for a reverse split if it means getting BCLI on the Nasdaq. There are a handful of us here who are not concerned with the repercussions of a r/s and believe that since it is happening from a position of strength, that it should not have a bad effect on the share price.
Another point I'd like to make clear. I am not saying BCLI is going to appreciate 800% in value like CUR at this time. And I agree that pre-commercialization/major JV partnership, $150-200M is a fair valuation. I was simply using them as an example of a company in the same arena that was able to up-list and go from $.50 (only $.128 higher than BCLI right now), and attract big pocket investors, without doing a reverse split.
By that example, BCLI could in theory up-list to the NYSE with a much lower share price, without having to do a reverse split, and from there attract more institutional investors. Will it happen? Doubtful. I was just throwing it out there as a possibility since I would have expected to see a new proxy by this point.
Whoops. Sorry about that. Got confused with Pluristem there for a second. That doesn't really change anything with the main point of my post though, other than illustrate that I am an idiot.
I have no idea what moves they are considering at BCLI headquarters. I still feel that going by what we have heard to this point, that they are looking to up-list to the Nasdaq. If that is so, then I stand by my previous posts that they will need to do a r/s. However, looking at CUR as an example and keeping in mind that Lebovits is very good at masking the truth, I am starting to wonder if a NYSE-MKT up-listing is a possibility for BCLI.
The caveat to all of this is that I am basing this all under the assumption that they want to up-list this year, as has been indicated. It is very doubtful that they would up-list without having big news to combine it with and I believe published Phase I/IIa data to be that news. If Fiorino feels that it is best to wait until they have Phase II interim data, then it could be a while and explain why we haven't seen a new proxy. Again though, going by what the company has been saying over the past year or so, it is hard to come to any other conclusion than them wanting to up-list this year.
Any thoughts would be appreciated!
Someone brought this up here the other day and it got me thinking.
I have been talking about a reverse split in order to up-list for a while now. It's not because I don't think BCLI has the potential to appreciate astronomically high in the future. If I didn't, I would have sold all of my shares into this rally. It's because to get to those astronomical gains the stock really needs core institutional investors. Most of those investors unfortunately have rules against investing in OTC-listed stocks.
BCLI has said on numerous occasions that they will probably up-list to the Nasdaq and have printed "such as the Nasdaq" in all of their filings. All indications are that this the index they'd like to up-list to for a few reasons, but also because of the Nasdaq's reciprocal collaboration with the Tel Aviv Stock Exchange. Because of this, logically one would think BCLI would need to do a r/s in order to meet the very minimum share price requirement in order to up-list to the Nasdaq-CM.
What has got me thinking more on this though is two items. 1. The Proxy and 2. CUR (Neuralstem).
BCLI let the proxy expire on April 14th, 2014 knowing full and well how trial results were so far successful, that they were about to enter the US market, and that they still had strong intentions as ever to up-list in the very near future. So why would they let it expire? Why have we not seen a new proxy (that would have a year long shelf life) filed in the 2 months since April? Once they issue a proxy we'll have to wait quite a while before the actual vote happens. If they wanted to time an up-list with the August release of published Phase I/IIa data, then that proxy needs to be out now.
Then I look at CUR. Also an Israeli company with an ALS trial, with an American base in MD. They did not do a reverse split and instead up-listed to the NYSE-MKT while their share price was around $.50. Since then, the stock price has risen about 800% to its current price of over $4.
If we want BCLI to go where we want it to go, it is going to get shorted. There is no way to avoid that. That's how things work when you play with the big boys.
BCLI would not r/s unless they did it in conjunction with an up-list. But saying there is no need for a r/s is a bit wishful thinking in my opinion. If they could do it great. However, there very minimum share price that BCLI needs to meet the requirement for the lowest rung of the Nasdaq, would be $2. That is a $500M market cap for BCLI, 8 X more than today. And I don't believe BCLI is aiming for that rung since as you said, once they up-list the volatility from shorts and being introduced to the big boys would put them at great risk of dropping back down fast and being de-listed. I believe BCLI will want more of a buffer and prefer to be on one of the more elite Nasdaq indexes. I think they'll be looking at around anywhere from $6-9 before they up-list. Without a r/s we are talking about over $1B in market capitalization. I really like this company, but sorry I just don't see that happening just yet. Would love to be wrong.
Nah, the older warrants had anti-dilution provisions. The new ones don't. Besides, we just saw 42M new shares hit the market and look what it did to the pps.